Inhalation Therapy Co.

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing a pipeline of drug candidates in oncology and immunology. The company utilizes its proprietary advanced polymer conjugate technology platform to create new drug candidates that improve the pharmacokinetics and pharmacodynamics of existing molecules. Originally founded as Inhale Therapeutic Systems, the company gained prominence for its pulmonary drug delivery technology, including the development of Exubera, the first inhaled insulin. Today, Nektar's lead programs include bempegaldesleukin (NKTR-214), an IL-2 pathway agonist, and rezpegaldesleukin (NKTR-358), a T-regulatory cell stimulator being developed for autoimmune diseases. The company maintains several high-profile partnerships with major pharmaceutical firms to advance its diverse clinical pipeline.